387 related articles for article (PubMed ID: 28112132)
1. Reduced-fluence photodynamic therapy and anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy in an Indian population.
Sen P; Bhende M; Sachidanandam R; Bansal N; Sharma T
Indian J Ophthalmol; 2016 Dec; 64(12):908-913. PubMed ID: 28112132
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of verteporfin photodynamic therapy in combination with anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Jain P; Anantharaman G; Gopalakrishnan M; Goyal A
Indian J Ophthalmol; 2018 Aug; 66(8):1119-1127. PubMed ID: 30038155
[TBL] [Abstract][Full Text] [Related]
3. Complete regression of branching vascular network in polypoidal choroidal vasculopathy by ranibizumab and photodynamic therapy, two case reports.
Iesato Y; Tanaka M; Murata M; Kitahara J; Hirano T; Kurenuma T; Yoshida N; Murata T
BMC Ophthalmol; 2018 Nov; 18(1):284. PubMed ID: 30390650
[TBL] [Abstract][Full Text] [Related]
4. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
5. Anti-vascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy with polyps resembling grape clusters.
Lee JH; Lee WK
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):645-51. PubMed ID: 26138657
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
[TBL] [Abstract][Full Text] [Related]
7. Comparing efficacy of reduced-fluence and standard-fluence photodynamic therapy in the treatment of polypoidal choroidal vasculopathy.
Ngo WK; Chee WK; Tan CS; Lim TH
BMC Ophthalmol; 2020 Apr; 20(1):150. PubMed ID: 32293353
[TBL] [Abstract][Full Text] [Related]
8. Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.
Sagong M; Lim S; Chang W
Am J Ophthalmol; 2012 May; 153(5):873-882.e2. PubMed ID: 22265146
[TBL] [Abstract][Full Text] [Related]
9. Incidence, outcomes, and risk factors for hemorrhagic complications in eyes with polypoidal choroidal vasculopathy following photodynamic therapy in Indian subjects.
Rishi P; Rishi E; Sharma M; Maitray A; Bhende M; Gopal L; Sharma T; Ratra D; Sen P; Bhende P; Rao C; Susvar P
Indian J Ophthalmol; 2017 Aug; 65(8):712-718. PubMed ID: 28820157
[TBL] [Abstract][Full Text] [Related]
10. Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab.
Byon IS; Kwon HJ; Kim SI; Shin MK; Park SW; Lee JE
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):534-41. PubMed ID: 25423633
[TBL] [Abstract][Full Text] [Related]
11. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
14. HALF-DOSE PHOTODYNAMIC THERAPY COMBINED WITH BEVACIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Lee JH; Lee WK
Retina; 2015 Aug; 35(8):1561-8. PubMed ID: 25768248
[TBL] [Abstract][Full Text] [Related]
15. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
[TBL] [Abstract][Full Text] [Related]
16. Anti-vascular endothelial growth factor monotherapy in the treatment of submacular hemorrhage secondary to polypoidal choroidal vasculopathy.
Cho HJ; Koh KM; Kim HS; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Sep; 156(3):524-531.e1. PubMed ID: 23769197
[TBL] [Abstract][Full Text] [Related]
17. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
Yoneda A; Wakiyama H; Kurihara J; Kitaoka T
Eur J Ophthalmol; 2020 Nov; 30(6):1473-1479. PubMed ID: 31476891
[TBL] [Abstract][Full Text] [Related]
18. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Kume A; Iijima H
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
[TBL] [Abstract][Full Text] [Related]
19. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
20. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
